Quantitative pancreatic MRI: a pathology-based review

Chouhan, Manil; Firmin, Louisa; Read, Samantha; Amin, Zahir; Taylor, Stuart A.

doi:10.1259/bjr.20180941

Cited by 13 publications

(8 citation statements)

References 108 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Dixon protocol was applied to measure the proton density fat fraction (PDFF) of the liver and pancreas since it has shown high accuracy when compared to histologic fat fraction. It has also shown a high correlation with MR spectroscopy but has a shorter acquisition and processing time and a significantly higher sensitivity over ultrasound or computed tomography methods [32, 33]. Additional details regarding the protocol, as well as measurement of visceral fat area, subcutaneous fat area, and percent liver fat were previously published by Lim and colleagues (2019) [31].…”

Section: Methodsmentioning

confidence: 99%

Genome-wide Association Study of Pancreatic Fat: The Multiethnic Cohort Adiposity Phenotype Study

Streicher

Lim

Park

et al. 2021

Preprint

View full text Add to dashboard Cite

Several studies have found associations between higher pancreatic fat content and adverse health outcomes, such as diabetes and the metabolic syndrome, but investigations into the genetic contributions to pancreatic fat are limited. This genome-wide association study, comprised of 804 participants with MRI-assessed pancreatic fat measurements, was conducted in the ethnically diverse Multiethnic Cohort-Adiposity Phenotype Study (MEC-APS). Two genetic variants reaching genome-wide significance, rs73449607 on chromosome 13q21.2 (Beta = −0.67, P = 4.50×10-8) and rs7996760 on chromosome 6q14 (Beta = −0.90, P = 4.91×10-8) were associated with percent pancreatic fat on the log scale. Rs73449607 was most common in the African American population (13%) and rs79967607 was most common in the European American population (6%). Rs73449607 was also suggestively associated with lower risk of type 2 diabetes (OR = 0.95, 95% CI = 0.89-1.00, P = 0.047) in the Population Architecture Genomics and Epidemiology (PAGE) Study and the DIAbetes Genetics Replication and Meta-analysis (DIAGRAM), which included substantial numbers of non-European ancestry participants (53,102 cases and 193,679 controls). Rs73449607 is located in an intergenic region between GSX1 and PLUT, and rs79967607 is in intron 1 of EPM2A. PLUT, a linkRNA, regulates transcription of an adjacent gene, PDX1, that controls beta-cell function in the mature pancreas, and EPM2A encodes the protein laforin, which plays a critical role in regulating glycogen production. If validated, these variants may suggest a genetic component for pancreatic fat and a common etiologic link between pancreatic fat and type 2 diabetes.

show abstract

Section: Methodsmentioning

confidence: 99%

Genome-wide Association Study of Pancreatic Fat: The Multiethnic Cohort Adiposity Phenotype Study

Streicher

Lim

Park

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…The Dixon protocol was applied to measure the proton density fat fraction (PDFF) of the liver and pancreas since it has shown high accuracy when compared to histologic fat fraction. It has also shown a high correlation with MR spectroscopy but has a shorter acquisition and processing time and a significantly higher sensitivity over ultrasound or computed tomography methods [47,48]. Additional details regarding the protocol, as well as measurement of visceral fat area, subcutaneous fat area, and percent liver fat were previously published by Lim and colleagues (2019) [46].…”

Section: Adiposity Measurementsmentioning

confidence: 99%

Genome-wide association study of pancreatic fat: The Multiethnic Cohort Adiposity Phenotype Study

et al. 2021

View full text Add to dashboard Cite

Several studies have found associations between higher pancreatic fat content and adverse health outcomes, such as diabetes and the metabolic syndrome, but investigations into the genetic contributions to pancreatic fat are limited. This genome-wide association study, comprised of 804 participants with MRI-assessed pancreatic fat measurements, was conducted in the ethnically diverse Multiethnic Cohort-Adiposity Phenotype Study (MEC-APS). Two genetic variants reaching genome-wide significance, rs73449607 on chromosome 13q21.2 (Beta = -0.67, P = 4.50x10-8) and rs7996760 on chromosome 6q14 (Beta = -0.90, P = 4.91x10-8) were associated with percent pancreatic fat on the log scale. Rs73449607 was most common in the African American population (13%) and rs79967607 was most common in the European American population (6%). Rs73449607 was also associated with lower risk of type 2 diabetes (OR = 0.95, 95% CI = 0.89–1.00, P = 0.047) in the Population Architecture Genomics and Epidemiology (PAGE) Study and the DIAbetes Genetics Replication and Meta-analysis (DIAGRAM), which included substantial numbers of non-European ancestry participants (53,102 cases and 193,679 controls). Rs73449607 is located in an intergenic region between GSX1 and PLUTO, and rs79967607 is in intron 1 of EPM2A. PLUTO, a lncRNA, regulates transcription of an adjacent gene, PDX1, that controls beta-cell function in the mature pancreas, and EPM2A encodes the protein laforin, which plays a critical role in regulating glycogen production. If validated, these variants may suggest a genetic component for pancreatic fat and a common etiologic link between pancreatic fat and type 2 diabetes.

show abstract

“…However, this study has limited applicability due to limited availability and high cost of secretin. 4,22,23 The recommended dose of secretin is around 0.2 µg/kg. The peak action of the injected secretin is around 3 to 5 minutes after administration and the duodenal lumen gets filled with the bicarbonate rich fluid after 5 minutes and the maximum Abbreviations: 3D, three-dimensional; LAVA, liver acquisition with volume acceleration; VIBE, volumetric interpolated breath-hold examination.…”

Section: Secretin Mrcpmentioning

confidence: 99%

Recent Advances in Pancreatic MR Imaging: A Guide on How, When, and Why to Perform

Srinivasan

Chatterjee

2020

Journal of Gastrointestinal and Abdominal Radiology

View full text Add to dashboard Cite

Imaging of the pancreas is often challenging because of its retroperitoneal location and unique set of pathologies. Conventional imaging modalities, such as transabdominal and endoscopic ultrasonography (EUS), computed tomography (CT), and magnetic resonance imaging (MRI), are well described in the literature. However, with modern demand for functional and molecular information from imaging studies, newer imaging modalities and modifications of existing modalities are developed. MRI is widely used as a problem-solving tool in pancreatic pathologies. Magnetic resonance cholangiopancreatography (MRCP) is an excellent technique for the depiction of the pancreatic ductal or biliary ductal pathologies. Newer modification of MRI including secretin MRCP, advanced diffusion-weighted imaging (DWI), perfusion imaging, and tissue composition analysis (fat and fibrosis quantification) add to the arsenal of MRI of the pancreas. In this review, we discuss the evolution of MRI of the pancreas and clinical application of advanced MR sequences.

show abstract

Quantitative pancreatic MRI: a pathology-based review

Cited by 13 publications

References 108 publications

Genome-wide Association Study of Pancreatic Fat: The Multiethnic Cohort Adiposity Phenotype Study

Genome-wide Association Study of Pancreatic Fat: The Multiethnic Cohort Adiposity Phenotype Study

Genome-wide association study of pancreatic fat: The Multiethnic Cohort Adiposity Phenotype Study

Recent Advances in Pancreatic MR Imaging: A Guide on How, When, and Why to Perform

Contact Info

Product

Resources

About